[1] Roberts R.PCSK9 inhibition-a new thrust in the prevention of heart disease:genetics does it again[J].Can J Cardiol,2013,29(8):899-901. [2] 张娜,李志勇,李林森.Ox-LDL与动脉粥样硬化的关系及中药抗氧化作用的研究进展[J]. 云南民族大学学报:自然科学版,2013,22(5):313-316. [3] 刘俊田.动脉粥样硬化发病的炎症机制的研究进展[J].西安交通大学学报:医学版,2015,36(2):141-152. [4] 王继贵.炎症生物标志物对心血管疾病的预测意义[J].医学研究杂志,2015,44(1):16-19. [5] 梁洁玲,王洋洋,司艳辉,等. MCP-1水平与颈动脉粥样硬化程度的相关性研究[J]. 黑龙江医学,2015,39(5):475-476. [6] 陈文强,黄小波,王宁群,等.陈皮半夏对颈动脉硬化家兔血管细胞黏附分子-1及基质金属蛋白酶-9表达的影响[J].中国中医药信息杂志,2013,20(11):34-36. [7] 吕占清,谷菲.超敏C反应蛋白联合血脂检测对诊断冠状动脉硬化的意义[J].中国社区医师,2015,31(17):106-108. [8] 胡立新.单纯性肥胖儿童hs-CRP、IL-6水平与胰岛素抵抗指数相关性研究[J].医学综述,2014,20(5):915-916. [9] 张安邦,高杰,李令根,等.相关炎症因子与动脉粥样硬化的关系[J].中国中西医结合外科杂志,2014,20(5):563-566. [10] Xu RX,Li S,Zhang Y,et al. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease[J]. Lipids Health Dis,2014,13:188-204. [11] Abifadel M,Guerin M,Benjannet S,et al.Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia[J].Atherosclerosis,2012,223(2):394-400. [12] Kosenko T,Golder M,Leblond G,et al.Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9(PCSK9)in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation[J].J Biol Chem,2013,288(12):8279-8288. [13] Leren TP.Sorting an LDL receptor with bound PCSK9 to intracellular degradation[J].Atherosclerosis,2014,237(1):76-81. [14] Araki S, Suga S, Miyake F, et al. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants[J]. Early Hum Dev,2014,90(10):607-611. [15] Kwakernaak AJ,Lambert G,Dullaart RP.Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins[J].Clin Biochem,2014,47(7/8):679-682. [16] Werner C,Hoffmann MM,Winkler K,et al.Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9)in patients with stable coronary disease on statin treatment[J].Vasc Pharmacol,2014,62(2):94-102. [17] Wu Q,Tang ZH,Peng J,et al.The dual behavior of PCSK9 in the regulation of apoptosis is crucial in Alzheimer's disease progression (Review)[J].Biomed Rep,2014,2(2):167-171. [18] 李风梅,刘忠民.人前蛋白转化酶枯草溶菌素9基因的研究进展[J].临床检验杂志,2014,32(3):219-221. [19] Spiring R,Tsui J,Shaw S.The Emerging Role of TLR and Innate Immunity in Cardiovascular Disease[J].Cardiol Res Pract,2012,2012:181394. [20] Lan H,Pang L,Smith MM,et al.Proprotein convertase subtilisin/kexin type 9(PCSK9)affects gene expression pathways beyond cholesterol metabolism in liver cells[J].J Cell Physiol,2010,224(1):273-281. [21] Ranheim T,Mattingsdal M,Lindvall JM,et al.Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9[J].J Cell Physiol,2008,217(2):459-467. [22] Hampton EN,Knuth MW,Li J,et al.The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain[J].Proc Natl Acad Sci U S A,2007,104(37):14604-14609. [23] Tarkowski A,Bjersing J,Shestakov A,et al.Resistin competes with lipopolysaccharide for binding to toll-like receptor 4[J].J Cell Mol Med,2010,14(6b):1419-1431. [24] Tang Z,Jiang L,Peng J,et al.PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages[J].Int J Mol Med,2012,30(4):931-938. |